Evaluation of R406 levels

The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services, is preparing to solicit proposals for an evaluation of R406 levels in a non-human primate model of bacterial sepsis. This research and development opportunity falls under the biotechnology research category, specifically focusing on special studies and analysis in chemical and biological domains. The pre-solicitation notice indicates a desire to conduct scientific research examining bacterial sepsis progression and potential therapeutic interventions using non-human primate models. The contract opportunity is currently in the pre-solicitation phase, with responses due by March 7, 2025, which suggests potential contractors should begin preparing detailed technical and scientific proposals. Interested parties should carefully review the forthcoming solicitation to ensure they meet the specialized research requirements and can demonstrate expertise in biotechnological research methodologies.

This procurement does not have a specific small business or disadvantaged business set-aside designation, which means all qualified contractors may compete for the opportunity. The contract is anticipated to involve sophisticated laboratory research and analysis, likely requiring advanced scientific capabilities and specialized equipment for studying bacterial sepsis models. While specific award values are not disclosed in the pre-solicitation notice, biotechnology research contracts of this nature typically range from $250,000 to $1.5 million depending on scope and complexity. The research will be conducted through the National Institutes of Health's National Heart, Lung, and Blood Institute, indicating a rigorous scientific evaluation process with high standards for technical competence. Potential contractors should be prepared to demonstrate extensive experience in biotechnological research, particularly in infectious disease modeling and non-human primate research protocols.